Islatravir not checked

Merck & Co. · MK-8591

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
16 in total · 2 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“ISL/ULO fixed-dose combination 2 mg/200 mg oral tablet administered qw for 96 weeks”In the company’s words, NCT07266831 on ClinicalTrials.gov
Tested for
Human Immunodeficiency Virus Type 1 (HIV-1) Infection (2 trials)
Main trialPhase 2/3
“Researchers are looking for new ways to treat HIV-1 (Human Immunodeficiency Virus Type 1). The usual (standard) treatment for HIV-1 is antiretroviral therapy (ART), which includes taking medicines to lower the amount of HIV-1 in the body. Standard ART helps people live longer, but people must take up to 3 medicines up to twice a day. Standard ART may also cause other health problems. Researchers want to know if a study ART works as well as a standard ART to treat HIV-1. The study ART combines 2 medicines, islatravir and ulonivirine, and is taken once a week. The goals of this study are to…”In the company’s words, NCT07266831 on ClinicalTrials.gov
Other names
ISL · MK-8591

Other drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

All 24 drugs for Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials16

TrialPhaseCompletesWhat it tests
Phase 2/3Recruiting 1 Feb 2029 A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Phase 2Active, not recruiting 10 Aug 2027 A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)
Phase 3Completed 21 Nov 2022 Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)
Phase 3Terminated 18 Jul 2023 Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)
Phase 3Terminated 4 Aug 2023 Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)
Phase 2Completed 8 Mar 2021 Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011)
Phase 2Completed 18 Mar 2022 Safety and Pharmacokinetics of Oral Islatravir (MK-8591) Once Monthly in Participants at Low Risk of Human Immunodeficiency Virus 1 (HIV-1) Infection (MK-8591-016)
Phase 2Withdrawn 25 Mar 2024 A Study of Islatravir (MK-8591) in Trans and Gender Diverse Participants (MK-8591-035)
Phase 2Completed 30 Jan 2025 Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013]
Phase 2Withdrawn 2 Oct 2025 Radiopaque Matrix MK-8591 Implant in Participants at Low-Risk for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591-043)
Phase 1Completed 19 Oct 2020 Pharmacokinetics of Islatravir in Participants With Severe Renal Impairment (MK-8591-026)
Phase 1Completed 9 Jul 2021 Islatravir and Methadone Pharmacokinetics (MK-8591-029)
Phase 1Completed 13 Sep 2021 Single-Dose Islatravir in Moderate Hepatic Impairment (MK-8591-030)
Phase 1Completed 15 Mar 2024 A Study of Doravirine and Islatravir as a Single Entity or Combination Therapy and the Effect of Food in Healthy Adult Participants (MK-8591A-055)
Phase 1Completed 23 Jun 2024 A Study of MK-8507 and Islatravir (MK-8591) in Healthy Adult Participants (MK-8507-016)
Phase 1Completed 14 Jul 2024 A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Islatravir

Following is part of Solo: you see every change to Islatravir the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in